Survival in the Correspondence J Department 23 January 1987 that agree Soysa purpose built tracks. of the Illingworth of stage Colorectal Controlled limitations Dukes's C colorectal cancer is made not of the patients. The mechanism is thought to be as follows: γ linolenic acid can bypass the enzyme deficiency, common to cells of many tumour types, of 6- desaturase, which normally converts dietary cis-linolenic acid to γ linolenic acid, an essential step in the synthesis of prostaglandin E₄. This and other prostaglandins have antimitastatic actions and can initiate the process of reverse transformation of tumour cells in culture, thus probably having an important role in modulating cell behaviour. This is the first reported controlled clinical trial of γ linolenic acid in human cancer and it has failed to show benefit in colorectal cancer.

We thank Efamol Ltd, Guildford, Surrey, for supplying the capsules containing γ linolenic acid and vitamin E and the inert capsules.


(Accepted 13 February 1987)

Controlled trial of γ linolenic acid in Dukes’s C colorectal cancer

Colorectal cancer is a common cause of death. This reflects the advanced stage of disease in many patients when the diagnosis is made and the limitations of treatment other than surgery. Cytotoxic drugs do not prevent relapse when given as an adjunct to surgery and do not increase the survival of patients with advanced disease. More effective forms of treatment are needed. Interest has been shown, at least by patients, in a nutritional approach to treatment, and there has been a drift towards centres for alternative treatment of cancer such as those in Bristol and Morecambe Bay, where diet plays a large part in the management programme. Controlled studies of dietary additives in the treatment of cancer have not, however, shown any benefit.

The diet used at the centre in Bristol includes a combination of γ linolenic acid and vitamin E (Efamol). γ Linolenic acid, an oil extract of the seed from the evening primrose plant (Oenothera lamarckiana), is a polyunsaturated fatty acid from which prostaglandin E₂ is synthesised in a process requiring vitamin C, pyridoxine, and zinc. Prostaglandin E₂ can favourably affect the growth characteristics of animal and human tumour cells maintained in culture.

We have evaluated γ linolenic acid in the treatment of colorectal cancer. The drug used was empirical but was considerably more than the dose suggested on theoretical grounds. We selected patients with Dukes’s C colorectal cancer because the residual tumour mass is small after operation, the relapse rate is high, and no other effective treatment is available. Moreover, metastases usually appear first in the liver and the highest concentration of γ linolenic acid would be in the portal circulation, circumstances which should maximise any therapeutic effect.

Patients, methods, and results

Approval for the study was granted by the local district ethical committee, and informed consent was obtained from each patient. Patients with Dukes’s C colorectal cancer were assigned at random within one month of operation to receive Efamol capsules containing γ linolenic acid 500 mg and natural vitamin E 10 mg or capsules that were identical in appearance but contained an inert placebo. Six capsules were given daily in divided doses for an indefinite period. All patients were also given six compound vitamin tablets daily each containing vitamin C 125 mg, pyridoxine 25 mg, and zinc sulphate 5 mg. There were 54 patients in the study. All patients had normal serum carcinoembryonic antigen concentrations, and results of liver function tests were normal. None of the patients had any evidence of metastatic disease before admission to the study. One patient stopped treatment after 12 months. Four patients failed to attend after admission to the study. Of the remaining 49 patients, 25 received γ linolenic acid and vitamin E and 24 received placebo. Their mean ages were 62.1 years (range 48-81) and 64.8 years (range 45-77) respectively.

The figure shows the survival rate for the two groups. Ten patients in the treatment group died, with a median survival of 12 months (range 6-42); 12 patients in the control group died, with a median survival of 12 months (range 6-42). In all cases death was due to local recurrent or metastatic liver disease or both; there was no difference in the pattern of disease in the two groups. No side effects of treatment were noted apart from occasional facial flushing, which was attributed to pyridoxine. Twenty seven patients survived, with a median follow up of 20 months (range 1 to 44 months) and 12 months (range 3 to 33 months) in the treatment and control groups, respectively.

Comment

A nutritional approach to treatment has been shown in limited studies to have tumour regulating properties in some types of human cancer but not colorectal cancer. Thus γ linolenic acid caused growth regression when added to cultured melanoma, hepatoma, osteogenic sarcoma, and oesophageal cells. Moreover, a striking reduction in liver size has been reported in patients with primary liver cancer taking γ linolenic acid, and there is preliminary evidence of a response to γ linolenic acid in patients with mesothelioma and astrocytoma (Abstract 161). Second congruent with essential fatty acids, prostaglandins and leukotrienes, London 24-27 March, 1985). The mechanism is thought to be as follows: γ linolenic acid can bypass the enzyme deficiency, common to cells of many tumour types, of 6- desaturase, which normally converts dietary cis-linolenic acid to γ linolenic acid, an essential step in the synthesis of prostaglandin E₂. This and other prostaglandins have antimitastatic actions and can initiate the process of reverse transformation of tumour cells in culture, thus probably having an important role in modulating cell behaviour.

This is the first reported controlled clinical trial of γ linolenic acid in human cancer and it has failed to show benefit in colorectal cancer.

We thank Efamol Ltd, Guildford, Surrey, for supplying the capsules containing γ linolenic acid and vitamin E and the inert capsules.